Gilead Sciences Acquires Ouro Medicines for $2.18 Billion, Boosts Inflammation Portfolio

Gilead Sciences has acquired Ouro Medicines for $2.18 billion to bolster its inflammation portfolio. The deal includes Ouro's key drug, gamgertamig, which is in the FDA fast-track process. Tesla has seen a 12% increase in European monthly sales, its first growth in over a year, and the European EV market subset grew by 16%. Broadcom warns of supply chain constraints in the AI infrastructure space due to high demand and capacity constraints at key manufacturers.